EPHX2 and Lewy body dementia: Thus, giving the role that neuroinflammation, OS, and mitochondrial dysfunction play in PD and the efficacy of inhibiting the activity of sEH in preclinical models, sEH is a putative new pharmacological target for the treatment of PD and other α-syn-related pathologies such as Lewis body disease (LBD) [142] (Figure 2 and Figure 3).